SABS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	4 197.00
Average Volume	17 853.00
Market Cap	24.37M
EPS	$-0.600 ( 2024-05-21 )
Next earnings date	( $-1.020 ) 2024-08-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-03	Skyler Jay S	Buy	0
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)

INSIDER POWER
70.08
Last 87 transactions
Buy: 19 550 691 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. Correlation

10 Most Positive Correlations
GPRO	0.913
GP	0.908
PETS	0.907
SSTI	0.906
PRTS	0.906
MKTW	0.905
APPS	0.904
AUUD	0.901
TBLT	0.901
AGRX	0.899

10 Most Negative Correlations
APXI	-0.92
ACGL	-0.905
SWAV	-0.905
TCOM	-0.903
GHRS	-0.902
DXJS	-0.901
HYAC	-0.898
AEAE	-0.897
IBKR	-0.896
COOP	-0.89

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SAB Biotherapeutics, Inc. Financials

Annual	2023
Revenue:	$2.24M
Gross Profit:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2023
Revenue:	$2.24M
Gross Profit:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2022
Revenue:	$23.90M
Gross Profit:	$20.61M (86.23 %)
EPS:	$-4.31

FY	2021
Revenue:	$60.88M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.394

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.